The Myelodysplastic syndromes (MDS) and Myeloproliferative neoplasms (MPN) Program is a highly interdisciplinary group of investigators dedicated to reducing the incidence and subsequent mortality of MDS/MPN. The program fosters interdisciplinary research in basic science, genetics, clinical medicine, cancer prevention, and epidemiology at Fred Hutch, the faculty at the University of Washington, and the clinical community to improve MDS/MPN prevention, detection, diagnosis and treatment. 

Program Strengths

Forty years ago, researchers at Fred Hutch developed bone marrow transplantation, which continues to be an effective option for patients with MDS and MPN. Dr. E. Donnall Thomas and his team proved it is possible to replace cancerous cells and stem cells with donated healthy cells that engraft within a patient’s bone marrow. The discovery has created an effective treatment option for many blood cancers, and earned Thomas the 1990 Nobel Prize in physiology or medicine.

lymphoma graphic

Dr. Joachim Deeg
STTR MDS/MPN Deputy Director

Dr. Deeg treats bone marrow failure such as aplastic anemia and blood cancers, such as myelodysplastic syndrome, leukemia, and myelofibrosis. His research interests are in pathophysiology, genetics and epigenetics of MDS (role of transcription factors in regulation), inflammatory responses and GVHD, separation of GVHD and GVL effects by AAT, and iron and allogeneic responses.